Christina Belza1,2,3, John C Wales1,2, Glenda Courtney-Martin1,2,3, Nicole de Silva1,2, Yaron Avitzur1,2,3,4, Paul W Wales1,2,3,5. 1. Research Institute, University of Toronto, Toronto, Canada. 2. Group for Improvement of Intestinal Function and Treatment (GIFT), University of Toronto, Toronto, Canada. 3. Transplant and Regenerative Medicine Centre, University of Toronto, Toronto, Canada. 4. Division of Gastroenterology, Hepatology and Nutrition, University of Toronto, Toronto, Canada. 5. Division of General and Thoracic Surgery, The Hospital for Sick Children, Toronto, Canada.
Abstract
BACKGROUND: SMOFlipid has a more diverse lipid profile than traditional Intralipid and has become the standard lipid for patients in our intestinal rehabilitation program. Our objective was to compare outcomes in neonates with intestinal failure (IF) who received SMOFlipid against those receiving Intralipid. METHODS: This was a retrospective cohort study of infants with IF with a minimum follow-up of 12 months in 2008-2016. Patients were stratified into 2 groups: group 1 received SMOFlipid; group 2 was a historical cohort who received Intralipid. The primary outcome was liver function evaluated using conjugated bilirubin (CB) levels. Statistical analysis included the Mann-Whitney U and χ2 tests, with an α value < 0.05 considered significant. Approval was obtained from our institutional review board. RESULTS: Thirty-seven patients were evaluated (17 = SMOFlipid, 20 = Intralipid). SMOFlipid patients were less likely to reach CB of 34 (24% vs 55%, P = 0.05), 50 µmol/L (11.8% vs 45%; P = 0.028), and did not require Omegaven (0% vs 30%; P = 0.014). CB level at 3 months after initiation of parenteral nutrition (PN) was lower in patients receiving SMOFlipid (0 vs 36 µmol/L; P = 0.01). Weight z-scores were improved for patients receiving SMOFlipid at 3 months (-0.932 vs -2.092; P = 0.028) and 6 months (-0.633 vs -1.614; P = 0.018). There were no differences in PN-supported patients or demographics between the groups. CONCLUSION: Use of SMOFlipid resulted in decreased development of IF-associated liver disease in patients with IF when assessed using biochemical tests.
BACKGROUND:SMOFlipid has a more diverse lipid profile than traditional Intralipid and has become the standard lipid for patients in our intestinal rehabilitation program. Our objective was to compare outcomes in neonates with intestinal failure (IF) who received SMOFlipid against those receiving Intralipid. METHODS: This was a retrospective cohort study of infants with IF with a minimum follow-up of 12 months in 2008-2016. Patients were stratified into 2 groups: group 1 received SMOFlipid; group 2 was a historical cohort who received Intralipid. The primary outcome was liver function evaluated using conjugated bilirubin (CB) levels. Statistical analysis included the Mann-Whitney U and χ2 tests, with an α value < 0.05 considered significant. Approval was obtained from our institutional review board. RESULTS: Thirty-seven patients were evaluated (17 = SMOFlipid, 20 = Intralipid). SMOFlipidpatients were less likely to reach CB of 34 (24% vs 55%, P = 0.05), 50 µmol/L (11.8% vs 45%; P = 0.028), and did not require Omegaven (0% vs 30%; P = 0.014). CB level at 3 months after initiation of parenteral nutrition (PN) was lower in patients receiving SMOFlipid (0 vs 36 µmol/L; P = 0.01). Weight z-scores were improved for patients receiving SMOFlipid at 3 months (-0.932 vs -2.092; P = 0.028) and 6 months (-0.633 vs -1.614; P = 0.018). There were no differences in PN-supported patients or demographics between the groups. CONCLUSION: Use of SMOFlipid resulted in decreased development of IF-associated liver disease in patients with IF when assessed using biochemical tests.
Authors: D R Shores; J E Bullard; S W Aucott; F D Stewart; C Haney; H Tymann; M R Miller; B A S Nonyane; K B Schwarz Journal: J Perinatol Date: 2015-08-27 Impact factor: 2.521
Authors: J E Van Aerde; D R Duerksen; L Gramlich; J B Meddings; G Chan; A B Thomson; M T Clandinin Journal: Pediatr Res Date: 1999-02 Impact factor: 3.756
Authors: David F Mercer; Brandy D Hobson; Ryan T Fischer; Geoffrey A Talmon; Deborah A Perry; Brandi K Gerhardt; Wendy J Grant; Jean F Botha; Alan N Langnas; Ruben E Quiros-Tejeira Journal: J Pediatr Gastroenterol Nutr Date: 2013-04 Impact factor: 2.839
Authors: Josep M Llop; Núria Virgili; José M Moreno-Villares; Pilar García-Peris; Teresa Serrano; Maria Forga; Joan Solanich; Ana M Pita Journal: Nutrition Date: 2008-07-24 Impact factor: 4.008
Authors: Robert H Squires; Christopher Duggan; Daniel H Teitelbaum; Paul W Wales; Jane Balint; Robert Venick; Susan Rhee; Debra Sudan; David Mercer; J Andres Martinez; Beth A Carter; Jason Soden; Simon Horslen; Jeffrey A Rudolph; Samuel Kocoshis; Riccardo Superina; Sharon Lawlor; Tamara Haller; Marcia Kurs-Lasky; Steven H Belle Journal: J Pediatr Date: 2012-05-11 Impact factor: 4.406
Authors: William Yakah; David Ramiro-Cortijo; Pratibha Singh; Joanne Brown; Barbara Stoll; Madhulika Kulkarni; Berthe C Oosterloo; Doug Burrin; Krishna Rao Maddipati; Raina N Fichorova; Steven D Freedman; Camilia R Martin Journal: Nutrients Date: 2021-01-12 Impact factor: 5.717
Authors: Suzan S Asfour; Belal Alshaikh; Latifah AlMahmoud; Haider H Sumaily; Nabeel A Alodhaidan; Mousa Alkhourmi; Hissah A Abahussain; Thanaa M Khalil; Bushra A Albeshri; Aroub A Alhamidi; Maha R Al-Anazi; Raneem S Asfour; Mountasser M Al-Mouqdad Journal: Nutrients Date: 2022-09-23 Impact factor: 6.706